Heat Biologics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Heat Biologics regular Real Value cannot be determined due to lack of data. The prevalent price of Heat Biologics is $0.0. Our model calculates the value of Heat Biologics from evaluating the firm fundamentals such as return on asset of -17.1, and Return On Equity of -31.12 as well as inspecting its technical indicators and probability of bankruptcy.
Heat Biologics Total Value Analysis
Heat Biologics is currently forecasted to have valuation of (34.74 M) with market capitalization of 60.46 M, debt of 1.93 M, and cash on hands of 96.38 M. The negative valuation of Heat Biologics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Heat Biologics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(34.74 M) | 60.46 M | 1.93 M | 96.38 M |
Heat Biologics Investor Information
The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. Heat Biologics recorded a loss per share of 1.15. The entity had not issued any dividends in recent years. The firm had 1-7 split on the 11th of December 2020. Based on the key indicators related to Heat Biologics' liquidity, profitability, solvency, and operating efficiency, Heat Biologics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Heat Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Heat Biologics has an asset utilization ratio of 17.95 percent. This suggests that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that Heat Biologics is more efficient with each dollar of assets it utilizes for everyday operations.Heat Biologics Ownership Allocation
Heat Biologics has a total of 25.4 Million outstanding shares. Heat Biologics retains 5.2 (percent) of its outstanding shares held by insiders and 10.77 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Heat Biologics Profitability Analysis
The company reported the previous year's revenue of 2.11 M. Net Loss for the year was (35.07 M) with loss before overhead, payroll, taxes, and interest of (16.71 M).Heat Biologics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Revenue Growth | 1.60% | |
| Forward Price Earnings | -1.62 | |
| Float Shares | 24.29M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Heat Stock
If you are still planning to invest in Heat Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Heat Biologics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |